Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 benralizumab trial in hypereosinophilic syndrome
MOH_2019-12-08_008543Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of benralizumab in hypereosinophilic syndrome (HES) (3 arms), sponsored by AstraZeneca. Primary endpoint: Time to first HES worsening/flare. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
benralizumab
03
Conditions
hypereosinophilic syndrome (HES)
Beyond the preview
Go deeper on MOH_2019-12-08_008543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-08_008543.